FDA Approves Novel Treatment for Coronary ISR
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Thu, 24 September 2026
What it is about
Who published it, and when
How it spread - 1 original report
Thu, 24 September 2026
1 report- dicardiology.com20:00first to report
Sept. 21, 2026 — Cordis, a provider of interventional cardiovascular and endovascular technologies, has announced that the U.S. Food and Drug Administration (FDA) has approved the Selution SLR (Sustained Limus Release) Drug-Eluting Balloon (DEB) for treating coronary in-stent restenosis (ISR). Physicians now have immediate access to the Selution SLR DEB, a drug-eluting balloon designed to deliver sustained sirolimus therapy without leaving a permanent implant behind. “FDA approval of the...